SCHEMBL4370840

SCHEMBL4370840

CC(C)(C)OC(=O)NCCCN(CCCN)C(=O)OC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.59
TDP1 Q9NUW8 1/20 0.54
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
CA1 P00915 11/20 0.43
CA2 P00918 11/20 0.43
CA12 O43570 7/20 0.43
CA9 Q16790 7/20 0.43
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39
DRD2 P14416 1/20 0.37
EPHX1 P07099 1/20 0.37
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472122 0.99 CA14 (0.62) CA14TDP1MAOAMAOBMEN1
SCHEMBL1919913 0.97 CA14 (0.60) CA14TDP1MAOAMAOBMEN1
SCHEMBL7631999 0.96 CA14 (0.62) CA14TDP1MAOAMAOBMEN1
SCHEMBL5919555 0.96 CA14 (0.58) CA14TDP1MAOAMAOBMEN1
SCHEMBL19340291 0.94 CA14 (0.57) CA14TDP1MAOAMAOBMEN1
SCHEMBL25238320 0.93 CA14 (0.56) CA14TDP1MAOAMAOBMEN1
SCHEMBL14107562 0.93 CA14 (0.56) CA14TDP1MAOAMAOBMEN1
SCHEMBL14107661 0.93 CA14 (0.56) CA14TDP1MAOAMAOBMEN1
SCHEMBL17396373 0.93 CA14 (0.56) CA14TDP1MAOAMAOBMEN1
SCHEMBL7264039 0.93 CA14 (0.58) CA14TDP1MAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024200838-A1 NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA NOSOPHARM (FR) 2024-10-03 WO disclosed
US-8901072-B2 Glycopeptide and lipoglycopeptide antibiotics with improved solubility THE MEDICINES COMPANY (US) 2014-12-02 US disclosed
US-8901072-B2 Glycopeptide and lipoglycopeptide antibiotics with improved solubility THE MEDICINES COMPANY (US) 2014-12-02 US disclosed
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY THE MEDICINES COMPANY (US) 2012-06-14 US disclosed
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY THE MEDICINES COMPANY (US) 2012-06-14 US disclosed
WO-2009034457-A1 ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, USES AND METHODS FOR THE PREPARATION THEREOF ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) 2009-03-19 WO disclosed
US-20080096974-A2 Polyamine-Metal Chelator Conjugates UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2008-04-24 US disclosed
US-20070213397-A1 Motuporamine mimic agents UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213397-A1 Motuporamine mimic agents MYADM, CD99, HNMT CA14 103/4885TDP1 1776/4885MAOA 742/4885
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY NGLY1, LGALS3BP, GYPA CA14 1504/4885TDP1 3648/4885MAOA 4731/4885
US-20080096974-A2 Polyamine-Metal Chelator Conjugates SLC7A1, SLC40A1, SRM CA14 2024/4885TDP1 2841/4885MAOA 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.